Phosplatin Therapeutics is harnessing immunogenic cell death (ICD) as an alternative ... and in combination therapy with PD-L1 immune checkpoint inhibition, and is in a phase 2 clinical trial ...

Programmed cell death-1, or PD-1, has become a headline-grabbing molecule best known for its role in cancer immunotherapies called checkpoint inhibitors. A study from Georgia Tech and Emory ...

Researchers at the University of Michigan Rogel Cancer Center have discovered a key reason why some cancers do not respond to ...